OmniAb, Inc. Common Stock earnings per share and revenue
On Nov 04, 2025, OABI reported earnings of -0.14 USD per share (EPS) for Q3 25, beating the estimate of -0.14 USD, resulting in a 1.96% surprise. Revenue reached 2.24 million, compared to an expected 5.76 million, with a -61.11% difference. The market reacted with a -3.72% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 9 analysts forecast an EPS of -0.09 USD, with revenue projected to reach 9.18 million USD, implying an decrease of -35.71% EPS, and increase of 310.16% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Takeda Pharmaceutical Company Limited - ADR
Report Date
Jan 30, 2026 For Q3 26
Estimate
$34.44
Actual
$65.64
Surprise
+90.61%
FAQ
What were OmniAb, Inc. Common Stock's earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, OmniAb, Inc. Common Stock reported EPS of -$0.14, beating estimates by 1.96%, and revenue of $2.24M, -61.11% below expectations.
How did the market react to OmniAb, Inc. Common Stock's Q3 2025 earnings?
The stock price moved down -3.72%, changed from $1.48 before the earnings release to $1.43 the day after.
When is OmniAb, Inc. Common Stock expected to report next?
The next earning report is scheduled for Mar 16, 2026.
What are the forecasts for OmniAb, Inc. Common Stock's next earnings report?
Based on 9
analysts, OmniAb, Inc. Common Stock is expected to report EPS of -$0.09 and revenue of $9.18M for Q4 2025.